Nykredit A S Invests $6.30 Million in Neurocrine Biosciences, Inc. $NBIX

Nykredit A S purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 37,372 shares of the company’s stock, valued at approximately $6,298,000.

Several other hedge funds have also recently bought and sold shares of the company. Geneos Wealth Management Inc. increased its position in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. DJE Kapital AG purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter worth about $28,000. Basecamp Wealth Advisors LLC grew its stake in Neurocrine Biosciences by 582.9% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after acquiring an additional 204 shares during the last quarter. Meeder Asset Management Inc. grew its stake in Neurocrine Biosciences by 651.6% in the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after acquiring an additional 202 shares during the last quarter. Finally, Cassaday & Co Wealth Management LLC purchased a new position in Neurocrine Biosciences during the 1st quarter valued at about $33,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NBIX has been the subject of a number of research reports. TD Cowen lifted their target price on shares of Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. The Goldman Sachs Group initiated coverage on shares of Neurocrine Biosciences in a research note on Tuesday, June 2nd. They set a “buy” rating and a $213.00 price objective for the company. Wall Street Zen downgraded Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Sunday, August 9th. Sanford C. Bernstein initiated coverage on Neurocrine Biosciences in a research note on Friday, May 22nd. They issued an “outperform” rating and a $221.00 target price on the stock. Finally, Wedbush upped their price objective on Neurocrine Biosciences from $185.00 to $194.00 and gave the company an “outperform” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Darin Lippoldt sold 10,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $179.60, for a total value of $1,796,000.00. Following the transaction, the insider owned 54,729 shares of the company’s stock, valued at approximately $9,829,328.40. This trade represents a 15.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 8,433 shares of Neurocrine Biosciences stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $178.72, for a total transaction of $1,507,145.76. Following the transaction, the insider owned 16,225 shares in the company, valued at $2,899,732. The trade was a 34.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 40,188 shares of company stock valued at $7,118,633 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $155.64 on Monday. The firm has a market capitalization of $15.82 billion, a PE ratio of 22.82, a P/E/G ratio of 0.73 and a beta of 0.38. The business has a 50-day moving average of $165.98 and a two-hundred day moving average of $150.46. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, beating the consensus estimate of $1.65 by $1.20. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%.The business had revenue of $959.00 million for the quarter, compared to analyst estimates of $891.16 million. During the same period in the previous year, the company posted $1.65 EPS. The company’s revenue was up 39.5% compared to the same quarter last year. As a group, research analysts anticipate that Neurocrine Biosciences, Inc. will post 7.25 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.